Extracellular matrix fragments and Toll-like receptor-2: reinforcing the mechanistic bridge from disc degeneration to inflammation in human tissue

Low back pain remains the single largest contributor to disability worldwide, and its burden is still growing. By current Global Burden of Disease projections, more than 800 million people will be affected by 2050 [1]. Intervertebral disc degeneration is one of the principal structural contributors to this burden [2]. However, current treatment strategies for intervertebral disc degeneration remain primarily focused on symptom control rather than reversal of the underlying degenerative process. Analgesics, physical therapy, interventional procedures, and surgery can ease symptoms, but none of them halt or reverse the tissue changes that make a disc painful [2]. What is needed is not merely another analgesic strategy, but a means of interrupting the molecular events that drive disc degeneration and pain. This, in turn, requires identifying where these pathological processes originate within human disc tissue.

Emerging evidence suggests that discogenic pain may result, at least in part, from aberrant activation of innate immune pathways. The healthy intervertebral disc is one of the largest avascular and aneural structures in the human body and has a limited intrinsic capacity for regeneration and repair [3]. As degeneration progresses, the extracellular matrix (ECM) is enzymatically cleaved, and the resulting fragments may act as damage-associated molecular patterns, or alarmins, capable of engaging Toll-like receptors (TLR) in the absence of infection [4]. This distinction is mechanistically important. Within the intact ECM, proteoglycans primarily serve structural and homeostatic functions and are largely immunologically inert. However, following proteolytic cleavage and release into the extracellular environment, these matrix-derived fragments may acquire bioactive properties and function as signaling ligands. Such conversion permits the rapid amplification of a danger signal without any requirement for new protein synthesis [4,5].

Soluble biglycan and decorin are recognized endogenous ligands of Toll-like receptor-2 (TLR-2) and TLR-4 and can promote cytokine and chemokine expression through NF-κB–dependent signaling pathways [4,5]. Within the intervertebral disc, these processes may contribute to a self-sustaining sterile inflammatory microenvironment in which cytokines, proteases, and neurotrophins amplify one another, thereby accelerating ECM degradation while promoting the ingrowth of nerves and blood vessels into tissue that is normally avascular and aneural [4]. Nerve growth factor represents one such neurotrophin, and its elevation during degeneration has been associated with disc innervation and pain [6]. This conceptual bridge from a mechanical disorder to a painful one is now widely recognized. Together, these findings support the evolving view that intervertebral disc degeneration is not merely a structural disorder, but also a biologically and immunologically mediated pain condition.

Despite substantial experimental evidence, direct validation in intact human intervertebral disc tissue remains limited. Existing mechanistic studies have largely relied on cultured cells, ex vivo disc systems, and animal models to show that matrix-derived fragments can engage innate immune receptors and elicit inflammatory signaling cascades. For example, Krock and colleagues demonstrated this relationship by exposing human intervertebral disc cells and ex vivo disc tissues to a defined fibronectin fragment and a TLR-2 agonist, resulting in proteoglycan depletion and increased cytokine production [7]. Individual proteoglycan fragments have similarly been documented in degenerate human and animal discs, including fragments of decorin, biglycan, fibromodulin, and lumican, though typically in separate tissues, cohorts, or model systems [3]. However, what remains limited is an integrated human-tissue analysis spanning the clinical spectrum of disc degeneration in which the fragmentation of multiple matrix proteoglycans, TLR-2 expression, and associated cytokine secretion profiles are evaluated concurrently.

In this issue of the Korean Journal of Pain, the study by Lama and colleagues [8] offers a valuable step forward by addressing this gap in human-tissue evidence. The authors examined twenty age- and sex-matched non-degenerated cadaveric control discs (Thompson grades 1–2), harvested within four hours postmortem to limit autolysis, together with thirty-five surgically excised discs obtained from patients with painful degeneration (Pfirrmann grades 3–5). Using these specimens, the authors assembled four complementary lines of evidence. First, Western blot analysis demonstrated proteolytic fragments of aggrecan and five small leucine-rich proteoglycans (decorin, biglycan, lumican, fibromodulin, and chondroadherin) within the 22–45 kDa range in advanced grade 4–5 discs, whereas such fragments were largely absent in control tissue. Second, immunofluorescence analysis showed that the organized pericellular distribution observed in non-degenerated discs became markedly reduced and dispersed in degenerated patient samples. Third, in the only experimental arm subjected to formal statistical analysis, cultured degenerated disc cells exhibited significantly increased TLR-2 expression compared with controls (P < 0.001). TLR-2 expression increased further following stimulation with the TLR-2 agonist Pam2CSK4 and decreased after treatment with the TLR-2 antagonist MMG-11, supporting functional involvement of TLR-2 signaling in these cells. Finally, cytokine antibody array analysis of disc-cell conditioned media demonstrated a pro-inflammatory secretory phenotype in degenerated samples, characterized by elevated IL-6, IL-8, and IL-1β, whereas control samples displayed a comparatively anabolic and growth factor–enriched profile, including transforming growth factor-β (TGF-β), epidermal growth factor (EGF), and vascular endothelial growth factor (VEGF).

Importantly, the study should be interpreted within the limits acknowledged by the authors themselves. The Western blot, immunofluorescence, and cytokine-array findings were presented as qualitative and hypothesis-generating, whereas formal statistical analysis was limited to the cell-based TLR-2 experiments. Thus, the value of the study lies not in definitive mechanistic proof but in the convergence of findings showing that matrix fragmentation, increased TLR-2 expression, and a pro-inflammatory secretome accompany advanced disc degeneration within a single human cohort. In this regard, the authors’ decision to interpret the findings as associative rather than causal represents a methodological strength.

This measured interpretation also helps define the studies now needed in the field. Quantitative analyses of matrix fragmentation, including densitometry and fragment-to-core ratios, would clarify the relationship between proteoglycan cleavage, TLR-2 expression, and inflammatory signaling. Because the present design is associative, it cannot determine whether specific fragments directly activate TLR-2 in disc cells. Experiments using purified proteoglycan fragments would therefore help establish causality and identify the most relevant candidate molecules [5,7]. The control design also has important limitations, as cadaveric tissue remains susceptible to postmortem artifacts, and the exclusively symptomatic patient cohort does not address why some degenerated discs are painful whereas others are not [2]. Finally, the relationship between TLR activation and pain remains inferential rather than directly demonstrated in this cohort. Longitudinal human studies and in vivo investigations examining whether TLR blockade modifies pain behavior will therefore represent important next steps [9].

Taken together, the study by Lama and colleagues supports the evolving view of painful disc degeneration as a matrix–immune disorder rather than merely an inevitable consequence of aging, while providing human-tissue evidence supporting further investigation of TLR-2 as a potential therapeutic target. The authors appropriately confine their conclusions to the level of association, and the principal contribution of the study lies in defining the next mechanistic questions with greater clarity. Addressing these questions will be essential for translating associative observations into established mechanisms and, ultimately, into therapies that extend beyond symptomatic treatment.